Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals

Mani

Published onApril 22, 2014

Updated on May 13, 2021

Novartis AG (NYSE:NVS) (VTX:NOVN) will acquire GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK)’s oncology unit for around $14.5 billion, while Glaxo will pay $5.25 billion for Novartis’ vaccines business.

The deal comes on the heels of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) revealing plans to acquire the wrinkle treatment maker Allergan Inc.

Deal to enhance firms’ core focus

While unveiling its fourth quarter earnings in February, GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK) said its Respiratory, Vaccines and HIV divisions were strengthened by new product...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

Novartis And GlaxoSmithKline In Multi-Billion Dollar Deals

Deal to enhance firms’ core focus

Login required to continue reading.

Get Your Business News